Skip banner links and go to contentU.S. Department of Health & Human Services * National Institutes of Health
National Heart, Lung, and Blood Institute:  Diseases and Conditions Index
Tell us what you think about this site
  Enter keywords to search this site. (Click here for Search Tips)  
U.S. Department of Health & Human Services National Institutes of Health Diseases and Conditions Index NIH Home NHLBI Home About This Site NHLBI Home NHLBI Home Link to Spanish DCI Tell us what you think
 DCI Home: Blood Diseases: Blood & Marrow Stem Cell Transplant: What Are the Risks

       Blood & Marrow Stem Cell Transplant
Skip navigation and go to content
What Is ...
Who Needs
What To Expect Before
What To Expect During
What To Expect After
What Are the Risks
Key Points
Links
 

What Are the Risks of a Blood and Marrow Stem Cell Transplant?

The main risks of a blood and marrow stem cell transplant are infection, graft-versus-host disease (GVHD), and graft failure.

Infection

You can easily get an infection after the transplant because your immune system is weak. The risk for infection decreases as your immune system recovers.

You can take steps to prevent infections, such as washing your hands and staying away from crowds. Doctors use medicines to prevent and treat infections.

Graft-Versus-Host Disease

GVHD is a common complication if you receive stem cells from a donor. In GVHD, the new stem cells attack your body.

Acute GVHD occurs within 90 to 100 days after the transplant. Chronic GVHD begins more than 90 to 100 days after the transplant or goes beyond 90 days after the transplant.

GVHD can be minor or life threatening. Signs and symptoms include:

  • A rash that starts on the palms and soles of your feet and spreads to your mid-section. Over time, the rash may cover your entire body. Skin can blister or peel if the rash is very bad.
  • Nausea (feeling sick to your stomach), vomiting, loss of appetite, abdominal cramps, and diarrhea. Doctors determine how bad GVHD is based on the severity of diarrhea.
  • Jaundice (yellowing of the skin and eyes) and abdominal pain, which indicate liver damage.

Medicines are used to treat GVHD. Acute GVHD is treated with glucocorticoids, such as methyl prednisone, prednisone in combination with cyclosporine, antithymocyte globulin, or monoclonal antibodies.

Chronic GVHD is treated with steroids—usually cyclosporine and prednisone on alternating days.

Older people, people who have had acute GVHD before, and people who received stem cells from mismatched or unrelated donors are more likely to develop GVHD.

Doctors can reduce your chances of getting GVHD by:

  • Closely matching your stem cells to your donor's through HLA tissue typing.
  • Using medicines to suppress your immune system.
  • Removing T cells from donor cells. T cells attack your body in GVHD.
  • Using umbilical cord blood as the source of donor cells.

Graft Failure

Graft failure occurs when your immune system rejects the new stem cells. It also can occur if not enough stem cells are used, the new stem cells are damaged during storage, or your bone marrow is damaged after the transplant.

Graft failure is more likely in people who receive less preparation for their transplants. People who get stem cells from a poorly matched donor also are more likely to have graft failure.

Other Risks

Complications from chemotherapy and radiation treatment (used to prepare for a transplant) can occur long after a transplant. These complications include infertility, cataracts, new cancers, and damage to the liver, kidneys, lungs, or heart.


What To Expect After Previous  Next Key Points


Email this Page Email all Sections Print all Sections Print all Sections of this Topic


Skip bottom navigation and go back to top
Department of Health and Human ServicesNational Institutes of Health National Heart, Lung, and Blood Institute
Blood Diseases | Heart and Blood Vessel Diseases | Lung Diseases | Sleep Disorders
NHLBI Privacy Statement | NHLBI Accessibility Policy
NIH Home | NHLBI Home | DCI Home | About DCI | Search
About NHLBI | Contact NHLBI

Note to users of screen readers and other assistive technologies: please report your problems here.